Literature DB >> 17697144

Strong cellular and humoral immune responses induced by transcutaneous immunization with HBsAg DNA-cationic deformable liposome complex.

Jing Wang1, Jin-hong Hu, Feng-qian Li, Guan-zhong Liu, Quan-gang Zhu, Ji-yong Liu, Hong-jun Ma, Cheng Peng, Fu-guo Si.   

Abstract

Transcutaneous immunization presents a major challenge on account of poor permeability of antigens through the skin barrier. To overcome this limitation, the deformable liposome could be a better method for transcutaneous delivery of these antigens. In this study, hepatitis B surface antigen (HBsAg) plasmid DNA-cationic complex deformable liposome was utilized as a mode for enhanced immunity against the antigen. Deformable liposome was prepared by conventional rotary evaporation method and characterized for various parameters such as vesicles shape and surface morphology, size and size distribution, entrapment efficiency, elasticity and stability. The immune stimulating activity was studied by measuring serum anti-HBsAg titre and cytokines level (interleukin-4 and interferon-gamma) following topical application of liposome in BALB/c mice and results were compared with deformable liposome encapsulated DNA applied topically as well as naked DNA and pure recombinant HBsAg, administered intramuscularly. It was observed that deformable liposome elicited a comparable serum antibody titre and endogenous cytokines levels compared to other vaccinations. The study signifies the potential of deformable liposome as DNA vaccine carriers for effective transcutaneous immunization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17697144     DOI: 10.1111/j.1600-0625.2007.00584.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  13 in total

Review 1.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

Review 2.  Particle based vaccine formulations for transcutaneous immunization.

Authors:  Ankit Mittal; Anne S Raber; Claus-Michael Lehr; Steffi Hansen
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

Review 3.  Nanocarriers for Skin Applications: Where Do We Stand?

Authors:  Neha Tiwari; Ernesto Rafael Osorio-Blanco; Ana Sonzogni; David Esporrín-Ubieto; Huiyi Wang; Marcelo Calderón
Journal:  Angew Chem Int Ed Engl       Date:  2021-10-01       Impact factor: 16.823

Review 4.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

5.  Effective transcutaneous immunization by antigen-loaded flexible liposome in vivo.

Authors:  Ni Li; Li-Hua Peng; Xi Chen; Shinsaku Nakagawa; Jian-Qing Gao
Journal:  Int J Nanomedicine       Date:  2011-12-08

Review 6.  Nanoparticles for transcutaneous vaccination.

Authors:  Steffi Hansen; Claus-Michael Lehr
Journal:  Microb Biotechnol       Date:  2011-08-19       Impact factor: 5.813

7.  Skin Delivery of siRNA Using Sponge Spicules in Combination with Cationic Flexible Liposomes.

Authors:  XueJiao Liang; JiaLiang Zhang; HuiLong Ou; Jun Chen; Samir Mitragotri; Ming Chen
Journal:  Mol Ther Nucleic Acids       Date:  2020-04-18       Impact factor: 8.886

8.  Comparison of electrically mediated and liposome-complexed plasmid DNA delivery to the skin.

Authors:  Loree C Heller; Mark J Jaroszeski; Domenico Coppola; Richard Heller
Journal:  Genet Vaccines Ther       Date:  2008-12-04

9.  Distribution characteristics of DNA vaccine encoded with glycoprotein C from Anatid herpesvirus 1 with chitosan and liposome as deliver carrier in ducks.

Authors:  Kunfeng Sun; Xin Li; Jinfeng Jiang; Anchun Cheng; Mingshu Wang; Dekang Zhu; Renyong Jia; Shun Chen; Yi Zhou; Xiaoyue Chen; Xiaoyu Wang
Journal:  Virol J       Date:  2013-03-16       Impact factor: 4.099

Review 10.  Transcutaneous antigen delivery system.

Authors:  Mi-Young Lee; Meong-Cheol Shin; Victor C Yang
Journal:  BMB Rep       Date:  2013-01       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.